Contact Us |
To increase the comprehension and usefulness of research studies for patients, the CIBMTR Consumer Advocacy Committee provides patient-level summaries of CIBMTR research articles.
Treatments for patients with moderate to severe acute GVHD have gotten better over time.
Tacrolimus helped patients with moderate acute GVHD live longer.
Cytogenetic testing can predict BMT outcomes in older patients with AML.
Transplant works for about 1 of every 3 older patients with AML.
Siblings 60 and older can donate blood-forming cells.
Older donors have similar quality of life after donation as younger donors.
Patients had less chronic GVHD after cord blood transplants.
Patients who received ATG had less acute GVHD.
Reduced-intensity BMT can work well for older patients with B-cell ALL.
For patients who had BMT when the disease was in the 1st complete remission, almost half (45%) were alive 3 years later.
About 20% of donors (1 in 5) at each time point had very poor QOL.
Parents tended to overestimate their child's QOL.
Younger children were more likely to have a lower QOL.
People were just as likely to be alive 3 years after transplant whether they had a matched sibling transplant or a haploidentical transplant.
Fewer people got GVHD after a haploidentical transplant.
At 2 years after transplant:
Most patients and caregivers thought transplant affected their family finances a medium or large amount.
Half of patients who worked before transplant were back to work.
Allo transplant may help people with high risk myeloma or myeloma that comes back early after an auto transplant live longer without the disease.
Younger people and people with no myeloma signs or symptoms before allo transplant lived longer without the disease.
Patients who had a haploidentical transplant had less chronic GVHD.
More than 2 years after transplant, patients who get an allo transplant are more likely to survive than patients who get an auto transplant.
Researchers think the care plans will help patients be healthier and less stressed after transplant.
Children with 43 or fewer chromosomes in their diseased cells had a higher risk of the leukemia coming back and dying after transplant compared to children with 44 or 45 chromosomes.
While more children may live longer because doctors can find better matched donors, disease factors still affect transplant outcomes.
A patient will be alive 6 months after starting treatment for acute GVHD.
Acute GVHD will get better with steroids.
The chance of getting GVHD did not depend on the patient's age.
Both allogeneic and autologous transplant recipients have a higher chance of getting a new cancer.
Most patients can find a well matched cord blood unit that is big enough in the registry, but few patients can find a very well matched cord blood unit.
Almost all patients younger than 20 years old can find a well matched adult donor or cord blood unit.
It is important to find the best donor as soon as possible, so the transplant isn't delayed. If a very well matched donor isn't available, it is better to use a well matched donor than to wait to try to find a very well matched one.
Bone marrow donors have severe side effects 3 times more often than blood stem cell donors.
Blood stem cell donors who get G-CSF do NOT get cancer, an autoimmune illness, or a stroke more often than those who don't get G-CSF.
About half of the older patients who get high dose chemo go into remission. However, the disease usually comes back within a year.
About 40% of older patients in remission who get an allo transplant live at least 2 years.
It is important for patients to talk with their doctor about an allo transplant as soon as they find out they have AML.
20% of patients with NBL who get an allo transplant go into remission for at least 5 years.
Patients with NBL who only get an allo transplant do better than patients who get an auto transplant first and then an allo transplant.
Salvage second hematopoietic cell transplantation in myeloma
To view PDF documents you will need Adobe Reader.